DE69232716D1 - Peptide mit thrombospondin-ähnlicher Aktivität und ihre therapeutische Verwendung - Google Patents

Peptide mit thrombospondin-ähnlicher Aktivität und ihre therapeutische Verwendung

Info

Publication number
DE69232716D1
DE69232716D1 DE69232716T DE69232716T DE69232716D1 DE 69232716 D1 DE69232716 D1 DE 69232716D1 DE 69232716 T DE69232716 T DE 69232716T DE 69232716 T DE69232716 T DE 69232716T DE 69232716 D1 DE69232716 D1 DE 69232716D1
Authority
DE
Germany
Prior art keywords
thrombospondin
peptides
activity
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232716T
Other languages
English (en)
Other versions
DE69232716T2 (de
Inventor
Jacob Eyal
George Paul Tuszynski
Bruce King Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WR Grace and Co Conn
WR Grace and Co
Philadelphia Health and Education Corp
Original Assignee
WR Grace and Co Conn
WR Grace and Co
Philadelphia Health and Education Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WR Grace and Co Conn, WR Grace and Co, Philadelphia Health and Education Corp filed Critical WR Grace and Co Conn
Application granted granted Critical
Publication of DE69232716D1 publication Critical patent/DE69232716D1/de
Publication of DE69232716T2 publication Critical patent/DE69232716T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69232716T 1991-05-22 1992-05-08 Peptide mit thrombospondin-ähnlicher Aktivität und ihre therapeutische Verwendung Expired - Fee Related DE69232716T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70525591A 1991-05-22 1991-05-22

Publications (2)

Publication Number Publication Date
DE69232716D1 true DE69232716D1 (de) 2002-09-12
DE69232716T2 DE69232716T2 (de) 2002-11-28

Family

ID=24832676

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232716T Expired - Fee Related DE69232716T2 (de) 1991-05-22 1992-05-08 Peptide mit thrombospondin-ähnlicher Aktivität und ihre therapeutische Verwendung

Country Status (7)

Country Link
US (1) US5654277A (de)
EP (1) EP0514721B1 (de)
JP (2) JP3706151B2 (de)
AU (1) AU1636492A (de)
CA (1) CA2063055A1 (de)
DE (1) DE69232716T2 (de)
ES (1) ES2181670T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
DE4203545A1 (de) * 1992-02-07 1993-08-12 Behringwerke Ag Spezifische antikoerper gegen aktivierte plaettchen, ihre herstellung und ihre verwendung in diagnose und therapie
AU5161296A (en) * 1995-04-21 1996-11-07 Allelix Biopharmaceuticals Inc. Anti-haemorrhagic peptides
AU5699996A (en) * 1995-06-02 1996-12-18 Allelix Biopharmaceuticals Inc. Anti-inflammatory thrombospondin-derived peptides
ATE307584T1 (de) * 1997-08-28 2005-11-15 Nissan Chemical Ind Ltd Mittel zur förderung und verstärkung der neovaskularisierung
EP1077995A1 (de) * 1998-05-22 2001-02-28 Abbott Laboratories Antiangiogenetisch wirkende substanz zur behandlung von krebs, arthritis und retinopathie
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CN1297930A (zh) * 1999-11-29 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人凝血栓蛋白30和编码这种多肽的多核苷酸
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
PL2776055T3 (pl) * 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
EP0478101B1 (de) * 1990-09-24 2001-08-29 W.R. Grace & Co.-Conn. Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität

Also Published As

Publication number Publication date
DE69232716T2 (de) 2002-11-28
AU1636492A (en) 1992-11-26
US5654277A (en) 1997-08-05
JP2005272480A (ja) 2005-10-06
ES2181670T3 (es) 2003-03-01
CA2063055A1 (en) 1992-11-23
JP3706151B2 (ja) 2005-10-12
EP0514721B1 (de) 2002-08-07
EP0514721A1 (de) 1992-11-25
JPH05178757A (ja) 1993-07-20

Similar Documents

Publication Publication Date Title
DE69132708D1 (de) Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität
DK14890D0 (da) Peptider med t-hjaelpercelleaktivitet
DE69424576D1 (de) Biologisch aktive tgf-beta1 und tgf-beta2 peptide
DE4393381T1 (de) Peptide
EP0406428A4 (en) Peptide derivatives and their use
NO924395D0 (no) Rekombinante menneske-faktor viii derivater
DE69223266D1 (de) Peptidderivate und deren Verwendung
DE69232716D1 (de) Peptide mit thrombospondin-ähnlicher Aktivität und ihre therapeutische Verwendung
SE8803847A0 (sv) Neuromodulerande peptid
DK64592D0 (da) Peptider til terapeutisk behandling
DK326889A (da) Polypeptid og polypeptidkompleks samt deres anvendelse
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
DE69430522D1 (de) Laufzeitstreuungssensor und umschalterdetektierschaltung mit dessen verwendung
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
DE69434024D1 (de) Auf humanen cortikalen thymozyten exprimierte oberflächenproteine und ihre verwendung
ATE277948T1 (de) Bpc peptid salze mit organ-schützender aktivität, deren herstellung und therapeutische verwendung
MC2002A1 (fr) Polypeptides interleukines-1alpha humaines recombines
IT8819791A0 (it) Peptidi ad attivita' farmaceutica.
ATE171460T1 (de) Synthetische amphipatische peptide mit antimikrobieller wirksamkeit
EE9400365A (et) Inimese gamma- interferooni antagonistid
KR960010685A (ko) 펩티드 및 그 용도
DE69124795D1 (de) Neutrophile stimulierende peptide
NO944670D0 (no) Enkeltkjedet peptid med hemoregulatorisk aktivitet
DE69420044D1 (de) Blutregulierende peptide
DE68928271D1 (de) Polypeptid mit Isoamylase-Aktivität und seine Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee